## Gravrand et al. (2022) Stratification of COVID-19 with SeptiCyte RAPID

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title	2
		or the abstract	
		(b) Provide in the abstract an informative and balanced summary of	2
		what was done and what was found	
Introduction			I
Background/rationale	2	Explain the scientific background and rationale for the investigation	4-5
		being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods		1 3 / 5 11 1	I.
Study design	4	Present key elements of study design early in the paper	6-12
Setting	5	Describe the setting, locations, and relevant dates, including periods	6-9
	3	of recruitment, exposure, follow-up, and data collection	0-7
6 ODortioinante	6	(a) Cohort study—Give the eligibility criteria, and the sources and	NA
6-9Participants	U	methods of selection of participants. Describe methods of follow-up	11/7
		Case-control study—Give the eligibility criteria, and the sources and	NA
		methods of case ascertainment and control selection. Give the	INA
		rationale for the choice of cases and controls	6.0
		Cross-sectional study—Give the eligibility criteria, and the sources	6-9
		and methods of selection of participants	NT.
		(b) Cohort study—For matched studies, give matching criteria and	NA
		number of exposed and unexposed	
		Case-control study—For matched studies, give matching criteria and	NA
		the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	19-21, 24
		confounders, and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	10-11
measurement		methods of assessment (measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	24
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	11-12,
		applicable, describe which groupings were chosen and why	19-20
Statistical methods	12	(a) Describe all statistical methods, including those used to control	11-12
		for confounding	
		(b) Describe any methods used to examine subgroups and interactions	11-12
		(c) Explain how missing data were addressed	11-12
		(d) Cohort study—If applicable, explain how loss to follow-up was	NA
		addressed	
		Case-control study—If applicable, explain how matching of cases	NA
		and controls was addressed	
		Cross-sectional study—If applicable, describe analytical methods	10-11
		taking account of sampling strategy	
		(e) Describe any sensitivity analyses	19-20
		( <u>-</u> )	1

## Gravrand et al. (2022) Stratification of COVID-19 with SeptiCyte RAPID

3*	(a) Papart numbers of individuals at each stage of study, ag numbers notantially	7
	(a) Report numbers of individuals at each stage of study—eg numbers potentially	
	eligible, examined for eligibility, confirmed eligible, included in the study,	
_	completing follow-up, and analysed	
=	(b) Give reasons for non-participation at each stage	7
	(c) Consider use of a flow diagram	7
4*	(a) Give characteristics of study participants (eg demographic, clinical, social) and	32-33
_	information on exposures and potential confounders	
_	(b) Indicate number of participants with missing data for each variable of interest	12
	(c) Cohort study—Summarise follow-up time (eg, average and total amount)	NA
5*	Cohort study—Report numbers of outcome events or summary measures over time	NA
	Case-control study—Report numbers in each exposure category, or summary	NA
_	measures of exposure	
	Cross-sectional study—Report numbers of outcome events or summary measures	11-16
16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and	14,16,19
	their precision (eg, 95% confidence interval). Make clear which confounders were	
_	adjusted for and why they were included	
_	(b) Report category boundaries when continuous variables were categorized	11
	(c) If relevant, consider translating estimates of relative risk into absolute risk for a	NA
	meaningful time period	
17	Report other analyses done—eg analyses of subgroups and interactions, and	19-20
	sensitivity analyses	
18	Summarise key results with reference to study objectives	23
19	Discuss limitations of the study, taking into account sources of potential bias or	23-25
	imprecision. Discuss both direction and magnitude of any potential bias	
20	Give a cautious overall interpretation of results considering objectives, limitations,	23-25
	multiplicity of analyses, results from similar studies, and other relevant evidence	
21	Discuss the generalisability (external validity) of the study results	25
		•
22	Give the source of funding and the role of the funders for the present study and, if	30
1 1 1	5*66	(c) Consider use of a flow diagram  4* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders  (b) Indicate number of participants with missing data for each variable of interest (c) Cohort study—Summarise follow-up time (eg, average and total amount)  5* Cohort study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers in each exposure category, or summary measures of exposure  Cross-sectional study—Report numbers of outcome events or summary measures  6 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included  (b) Report category boundaries when continuous variables were categorized  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  7 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses  8 Summarise key results with reference to study objectives  9 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias  60 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence  10 Discuss the generalisability (external validity) of the study results

<sup>\*</sup>Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.